The Effect ofHypotensive Drugs on Cardiovascular Responses The adrenergic inhibitory drugs have been used in the treatment of hypertension for many years, e.g. guanethidine ('Ismelin'), bethanidine ('Esbatal'), methyldopa ('Aldomet'), or debrisoquine ('Declinax'). While theie are differences between them, with less postural and exercise hypotension with methyldopa (Oates et al. 1965 , Prichard et al. 1968 , Heffernan et al. 1971 , they all interfere with important cardiovascular homeostatic reflexes that are mediated largely by sympathetic constrictor fibres to alpha-adrenergic receptors.
There are a number of physiological events that increase the hypotensive action ofsympathetic inhibitory drugs:
(1) Blood vessel tone is maintained by alterations in sympathetic vasoconstrictor activity, and this activity is increased when standing to counteract the hydrostatic effect of the weight of the column of blood, compared to the supine position. Sympathetic inhibitory drugs therefore produce a larger fall of blood pressure in the standing position when the need for sympathetic constriction is increased.
(2) While posture is the most important factor, increased demand of various vascular beds, muscle dilatation from exercise, skin dilatation from a hot environment, splanchnic dilatation after a meal, all tend to result in a further fall of blood pressure when vasoconstriction that would otherwise occur is inhibited.
(3) When there is an obstruction to venous return as seen in straining at the stool or more convenient for the laboratory, Valsalva's manoeuvre, there is a need for increased vaso-constriction to maintain arterial pressure as there is a reduction in cardiac output secondary to the reduction in venous return to the heart. A potentially dangerous greater fall in blood pressure from this source is clearly much more likely to occur if the agent producing sympathetic inhibition also results in constipation when more prolonged rises in intra-abdominal and intrathoracic pressure occur in defmcation. When ganglion-blocking drugs were used in hypertension, constipation resulted from their parasympathetic blocking action. (4) A reduction of blood volume requires additional vasoconstriction to maintain blood pressure. This occurs in the early hours of the day when blood volume is reduced, a change that is greater in hypertensives than normotensives. This diurnal variation in blood volume is probably responsible for the greater incidence of excessive hypotension seen in the early hours of the day, on standing or after exercise.
The effect of these various physiological stresses is additive and clearly an excessive fall in blood pressure in patients being treated by these drugs is more likely to occur for instance in the early hours of the day, performing exercise in the standing position, in a hot environment after a good meal, e.g. 2 a.m. at a 'dinner dance'. Response ofBloodPressure to Physiological Stimuli in Hypertensive Patients Treated with Beta-adrenergic Blocking Drugs The action on response ofbloodpressure to posture and exercise: From the earliest studies it was noted that there was an absence of postural and exercise hypotension when blood pressure had been lowered by oral propranolol (Prichard & Gillam 1964 . This has been confirmed with intra-arterial recordings of blood pressure, for posture and supine exercise (Prichard, Aellig & Richardson 1970) , and for posture and erect exercise (Prichard, Gillam & Graham 1970 ). These later investigations showed an increased peripheral resistance on changing from supine to standing position. The to the effects seen on sympathetic inhibitory drugs. However, the rise in blood pressure on exercise after beta blockade is less than that seen in the absence of a beta-blocking agent (Shinebourne et al. 1967) .
Studies with other beta-receptor blocking drugs have shown an absence of postural hypotension when blood pressure is lowered by beta-receptor blockade (Simpson 1974) .
We have recently confirmed the absence of postural and exercise hypotension with atenolol in contrast to sympathetic inhibitory drugs. Fig 1 illustrates a patient who had supine diastolic pressures on bethanidine of 110-115 mmHg, whose pressures fell to levels of 70-90 mmHg on standing. When atenolol was administered supine diastolic blood pressure was reduced to 80-90 mmHg and there was no longer any fall of blood pressure on standing. Similarly, Fig 2 shows another patient with poor control of the supine blood pressure, with diastolic levels of 110-124 mmHg, with pressures falling after exercise, 24 step-ups onto a 9 inch platform in 1 minute, to levels as low as under 60 mmHg. When atenolol was administered, supine diastolic pressure was reduced to around 80 mmHg and there was a loss of the exercise hypotension.
There are several sources of possible bias when a new drug is given to a patient who is already receiving treatment. However a within-patient randomized trial with bethanidine, methyldopa and propranolol has been carried out to verify the initial observations (Prichard et al. 1976 (Fig 3) . There is a considerable drop in blood pressure on standing and on exercise with bethanidine, not seen with propranolol, while methyldopa gives an intermediate effect.
The effect ofincreasing environmental temperature:
The response of blood pressure to posture and exercise at various environmental temperatures ..ii from 7°C to 30°C has been studied (Prichard, Gillam & Graham 1970) . As temperature was increased, there was an increased postural and exercise hypotension in patients treated with bethanidine and guanethidine. This is presumably due to increasing vasodilatation of skin blood vessels without adequate vasoconstriction occurring in other vessels to compensate. After treatment with propranolol alterations in environmental temperature did not affect the response of blood pressure to posture and exercise.
The action on Valsalva's manwuvre: The intravenous administration of a beta-adrenergic blocking drug reduces the overshoot after cessation of effort without reducing the vasoconstriction that occurs during effort (Prichard & Gillam 1966) . Prolonged oral administration of propranolol does not inhibit the vasoconstriction occurring during the effort phase of Valsalva's manoeuvre, in contrast to the inhibited vasoconstriction on bethanidine, guanethidine or methyldopa (Prichard, Gillam & Graham 1970).
Other Important Side Effects While methyldopa produces less postural and exercise hypotension than sympathetic neurone inhibitory drugs characteristic of drugs that act centrally, it results in a high incidence of sedation (Johnson et al. 1966 , Oates et al. 1965 , Prichard et al. 1968 ). Methyldopa is thought to be incorporated in the metabolic pathway of noradrenaline to produce the false transmitter amethyl noradrenaline to produce its central alpha-receptor stimulation (Henning & Rubenson 1971 , Finch & Haeusler 1973 . Clonidine, on the other hand, acts directly to stimulate central alpha receptors and produce its hypotensive effect (Haeusler 1975 , Schmitt 1975 . However, clonidine also results in a high incidence of drowsiness and tiredness and, in addition, because of its atropine-like side effects, principally dry mouth and constipation (Davidov et al. 1967 , Amery et al. 1970 , Onesti et al. 1971 .
Another potentially serious side effect can occur with clonidine if the drug is stopped abruptly. The patient may experience within 8 to 24 hours an exaggerated elevation of blood pressure, with an associated rise of urinary and plasma catecholamines (Hunyor et al. 1973 ). This withdrawal syndrome has been treated by intravenous phentolamine to lower the blood pressure, and propranolol may be used to control any tachycardia (Hunyor et al. 1973 ). The pressor response can be treated by intravenous clonidine, and oral clonidine (0.3-0.6 mg) is also effective, but the onset of action is slower (Raftos et al. 1973) . The incidence of pressor responses is probably fairly low but the syndrome does not occur if the drug is gradually discontinued during a week.
Patients should therefore be advised against stopping the medication abruptly and they should always carry with them several spare tablets and ensure that they do not run out.
There are two important untoward effects from the administration of beta-adrenergic blocking drugs that should be avoided with foresight in patient selection: heart failure and asthma. Patients in overt heart failure, or patients with incipient left ventricular insufficiency (they may have no signs of heart failure on physical examination or chest X-ray), are critically dependent on sympathetic activity to the heart to maintain their cardiac output. Those patients with left ventricu lar insufficiency should not be given a beta-receptor blocking drug without prior administration of digitals and diuretics. If these drugs alleviate the dyspncea it is reasonable, with extra caution, to begin beta-blocking treatment. There have been reports that patients who have been put into failure by propranolol have been subsequently able to tolerate the drug after the administration of digoxin and a diuretic (Prichard & Gillam 1966 , Amsterdam et al. 1969 . When heart failure is uncontrolled beta-adrenergic blocking drugs should not be given. It should be noted that betaadrenergic inhibitory drugs with intrinsic sympathomimetic stimulating action can also precipitate heart failure, for instance, alprenolol (Lund-Larsen & Sivertssen 1969 , Lyon & Nevins 1971 , INPEA (Del Bianco et al. 1966) , oxprenolol (Bianchi et al. 1969 , Forrest 1972 ) and pronethalol (Apthorp et al. 1964 ). There is no evidence that the direct membrane effect contributes significantly to heart failure (Coltart etal. 1971) .
It must be emphasized that caution must be exercised with small doses as the most dramatic change in the sympathetic environment of the heart takes place when treatment is begun with a beta-adrenergic receptor blocking drug, i.e. the small starting dose (Prichard 1974) . In one study, 7 out of 8 life-threatening adverse reactions due to impaired cardiac function were receiving a very small dose of less than 40 mg a day of propranolol (Greenblatt & Koch-Weser 1974) . The small percentage increase in dose levels entails less risk of suddenly precipitating heart failure than when dosage is begun. We have given beta-receptor blocking drugs to a total of over 300 patients with dosage of up to 4000 mg of propranolol or sotalol daily, and our only case of sudden cardiac decompensation was at the commencing dose of 10 mg of propranolol four times daily.
All nonselective beta-adrenergic blocking drugs are likely to produce a significant increase in airways resistance in asthmatic subjects due to inhibiting sympathetic tone in bronchial smooth muscle (Beumer 1974) . Even the cardioselective agents only show modest selectivity; a serious increase in airways resistance has been reported with practolol (Waal-Manning & Simpson 1971 ).
Long-term Values ofBeta-adrenergic Blocking Drugs Hitherto effective antihypertensive drugs have failed to reduce the increased incidence of the manifestations of ischemic heart disease. There is evidence that this may not be the case with betaadrenergic blocking drugs.
Cardioprotective Effect
There is some evidence that beta-adrenergic blocking drugs may exert a cardioprotective action. They reduce the tachycardia and arrhythmias of everyday stress in pilots undergoing simulated flight (Eliasch et al. 1967) , in public speaking (Taggart et al. 1973a ), racing-car driving (Taggart & Carruthers 1972) , motor-car driving (Taylor & Meeran 1793a) and travelling as a passenger by car or by air (Taylor & Meeran 1973b) .
There is evidence in experimental animals to indicate that beta-adrenergic blocking drugs reduce the size of acute myocardial infarcts and that this is reflected in associated ST segment changes (Maroko et al. 1971) . Evidence from man has shown that various beta-adrenergic blocking drugs reduce the ECG changes associated with ischmmia at rest and on exercise (Prichard, Aellig & Richardson 1970) . Pelides et al. (1972) , using multiple precordial leads, demonstrated that the acute administration of practolol reduces the degree and area of ST segment depression in patients with acute myocardial infarction. These observations have been confirmed (Hjalmarson et al. 1976) . In this connection the evidence afforded by the observations of Fox et al. (1975) is of interest. It was found that ischoemic patients matched for severity of pain, sex, age and previous cardiac history had significantly less severe ischmmic episodes while receiving beta-adrenergic blocking drugs compared to those patients who were not on betaadrenergic blocking drugs.
There have also been a number of studies in post-infarction patients that have demonstrated a reduction in recurrence of myocardial infarction and or sudden death in those patients given beta-adrenergic blocking drugs (Wilhelmsson et al. 1974 , Ahlmark et al. 1974 , Multicentre Trial 1975 . Similar results have been found in patients with angina pectoris (Lambert 1976) .
There seems therefore considerable evidence for a cardioprotective effect in high-risk patients, i.e. post-myocardial infarction. There has been a recent study to suggest that propranolol-treated patients with hypertension have a lower incidence of myocardial infarction than those not given beta adrenergic blocking drugs (Stewart 1976) .
Vasculoprotective Effects
Beta-adrenergic blocking drugs, other than merely lowering the blood pressure at rest or on exercise, have what could be termed an immediate vasculoprotective effect as they reduce the rate of systolic pressure and therefore the force of the systolic pressure wave. However, they have a number of other effects that may be beneficial in inhibiting the vascular degenerative process. While beta-adrenergic blocking drugs do not prevent the rise in catecholamines associated with various forms of stress, they abolish the rise in free fatty acids and triglycerides in response to racing-car driving (Taggart & Carruthers 1972 , Taggart et al. 1973b ) public speaking (Taggart et al. 1973a ) and being a passenger in an airliner (Carruthers et al. 1973 ). This action may be important in breaking a postulated chain on the effect of stress producing atheroma (Carruthers 1969 , Carruthers et al 1973 . The levels of cholesterol are not affected in man but experimentally the administration of propranolol to rabbits fed a high cholesterol diet has been found to reduce the development of atheromatous lesions (Whittington-Coleman et al. 1973) .
There have been a number of other actions reported that may be relevant to a long term vasculoprotective effect. Propranolol, in relatively small doses, was found to return the abnormal sensitivity of platelets to aggregation by adenosine diphosphate in patients with angina pectoris to the level seen-in normals (Frishman et al. 1974 ). Another observation that may help blood flow in compromised vessels is the observation that alprenolol reduces blood viscosity (Dintenfass & Lake 1976) . Finally, propranolol has been shown to reduce the rise in clotting factor VIII induced by adrenaline (Ingram & Jones 1966) .
Summary
Beta blockers have the advantage when used in the treatment of hypertension of not producing either postural or exercise hypotension. This hasbeen shown with all beta-blocking drugs. Important side effects can be avoided by proper patient selection, avoiding all beta-blocking drugs where heart failure is likely to be precipitated and nonselective drugs should not be used in patients with asthma. There is considerable evidence that beta-blocking drugs are cardioprotective and there is evidence coming forward that they may be vasculoprotective, but this is still in the realm of speculation.
